-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on InflaRx, Lowers Price Target to $14

Benzinga·03/20/2026 12:43:24
Listen to the news
Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $22 to $14.